论文部分内容阅读
目的:探讨多潘立酮片治疗功能性消化不良的临床研究。方法:选取我院2015年5月到2016年5月收治的70例患者为研究对象,随机将患者分为观察组和对照组,两组各35例,对照组给予多潘立酮(西安杨森制药有限公司生产)每天三次,每次10毫克;观察组给予多潘立酮(丽珠医药集团生产),每天三次,每次10毫克。两组连续治疗四周。结果:观察组治疗后腹痛、烧心、食欲不振等症状明显优于对照组,差异显著,具有统计学意义(P<0.05);两组治疗前症状总积分均得到改善,但观察组改善效果优于对照组(P<0.05);两组患者胃排空率比较无显著差异(P>0.05)。结论:多潘立酮(丽珠医药集团生产)是治疗功能性消化不良的主要药物。
Objective: To investigate the clinical study of domperidone tablets in the treatment of functional dyspepsia. Methods: Seventy patients admitted to our hospital from May 2015 to May 2016 were selected as study subjects. Patients were randomly divided into observation group and control group, 35 cases in each group and domperidone in control group (Xi’an Janssen Pharmaceutical Co., Ltd. Production) three times a day, each 10 mg; the observation group was domperidone (Livzon Pharmaceutical Group production), three times a day, each 10 mg. Two groups of continuous treatment for four weeks. Results: The symptom such as abdominal pain, heartburn and loss of appetite in the observation group were significantly better than those in the control group (P <0.05). The total symptom scores of both groups were improved before treatment, but the observation group had better effect (P <0.05). There was no significant difference in gastric emptying rate between the two groups (P> 0.05). Conclusion: Domperidone (manufactured by Livzon Pharmaceutical Group) is the main drug for the treatment of functional dyspepsia.